Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed a Current Report (8-K) on July 25, 2002, detailing events that occurred on July 24 and July 25, 2002. The primary purpose of this filing was to announce the issuance of two press releases on these dates. While the specific content of the press releases is not detailed within the 8-K itself, their inclusion as exhibits indicates they contain material information that the company deemed important enough to disclose to investors and the public.
Key Highlights
- 1Regeneron Pharmaceuticals, Inc. filed an 8-K on July 25, 2002, reporting on events from July 24 and July 25, 2002.
- 2The report's main purpose was to furnish copies of two press releases issued by the company.
- 3Press Release dated July 24, 2002 is included as Exhibit 99(a).
- 4Press Release dated July 25, 2002 is included as Exhibit 99(b).
- 5The 8-K filing indicates that these press releases likely contain significant updates or announcements relevant to investors.
- 6The company's principal executive offices are located at 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707.
- 7The filing was signed by Stuart Kolinski, Vice President & General Counsel.